An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients
Recruiting in Palo Alto (17 mi)
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: Psoriasis Treatment Center of Central New Jersey
No Placebo Group
Approved in 3 Jurisdictions
Trial Summary
What is the purpose of this trial?A single center study of 30 patient receiving Narrowband UVB phototherapy three times weekly for 12 weeks. Patients will be evaluated through week 36 to evaluate maintenance of response.
Eligibility Criteria
Inclusion Criteria
Male or female adults ≥ 18 years of age.
Diagnosis of chronic plaque-type psoriasis for at least 6 months
Moderate to Severe plaque psoriasis as defined by BSA ≥10 PASI ≥12 IGA ≥3
+3 more
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Open Label Narrowband UVB phototherapyExperimental Treatment1 Intervention
Open Label Narrowband UVB phototherapy for 12 weeks.
Narrowband UVB phototherapy is already approved in European Union, United States, Canada for the following indications:
🇪🇺 Approved in European Union as Narrowband UVB phototherapy for:
- Atopic dermatitis (eczema)
- Psoriasis
- Vitiligo
🇺🇸 Approved in United States as Narrowband UVB phototherapy for:
- Atopic dermatitis (eczema)
- Psoriasis
- Vitiligo
- Pityriasis lichenoides
- Pityriasis rosea
- Prurigo nodularis
🇨🇦 Approved in Canada as Narrowband UVB phototherapy for:
- Atopic dermatitis (eczema)
- Psoriasis
- Vitiligo
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Elise NelsonEast Windsor, NJ
Loading ...
Who Is Running the Clinical Trial?
Psoriasis Treatment Center of Central New JerseyLead Sponsor